EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The real-world burden of atopic dermatitis: MEASURE-AD results from Brazil, Mexico, and Argentina

Catalina Rincón Pérez, Valeria Aoki, Roberta F Criado, Martti Antila, Maria Valeria Angles, Tania Ferreira Cestari, Delfina Guadalupe Villanueva Quintero, Gabriel Magariños, Carla Castro, Adriana López Tello-Santillán, Magda Weber, Daniel Lorenzini und 9 weitere

Anais Brasileiros de Dermatologia · 2025

DOI: 10.1016/j.abd.2024.05.011 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anais Brasileiros de Dermatologia, 2025. Verfasst von Catalina Rincón Pérez und 20 weiteren Autor:innen. Beteiligte Einrichtung: GA(2)LEN Atopic Dermatitis Center of Reference and Excellence, Medical Specialty Unit, Secretaria de la Defensa Nacional, CDMX, Mexico. Electronic ad…. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Cost of Illness. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer, AbbVie Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Atopic dermatitis (AD) burden increases with disease severity.

Objective

Characterize the real-world burden of AD in Brazil, Mexico, and Argentina.

Methods

MEASURE-AD enrolled patients (≥12-years old) with moderate to severe AD receiving or candidates for systemic therapy between December 2019-December 2020. Patient characteristics, treatments, and outcomes were recorded during one office visit. Primary outcome measures included worst itch/past 24 hours (Worst Pruritus Numerical Rating Scale [WP-NRS]), quality of life (QoL, Dermatology Life Quality Index [DLQI] and Children’s DLQI [CDLQI]).

Results

Of 180 patients (adults, n = 157; adolescents, n = 23), 52.2% were male, the mean (SD) age was 33.8 (17.0) years, and all were receiving AD treatment (65.6% systemic therapy). Severe pruritus (WP-NRS ≥ 7) was reported by 54.4% (adults, 57.3%; adolescents, 34.8%). A very/extremely large effect on QoL (DLQI/CDLQI ≥ 11) was reported among 50.0% of patients ≥ 16 years old and 42.9% of patients 12-15 years old. The mean Eczema Area Severity Index (EASI) was 17.0 (adults, 17.7; adolescents, 12.4); 3.9% of patients had clear skin (EASI 0) and 26.7% had severe AD (EASI 23-72). Over the previous 6 months, 0, 1-2, 3-4, 5-6, and > 6 flares were reported by 8.3%, 27.2%, 31.1%, 11.7%, and 15.6% of patients, respectively. On average, flares lasted 15.2 days (adults, 15.9 days; adolescents, 11.1 days). Study limitations: Patient self-reported information and recall during one office visit.

Conclusions

Despite treatment, disease severity and impact on QoL were high, suggesting that AD is not adequately controlled in all patients, highlighting a considerable unmet need for effective treatments to reduce AD burden.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicCost of IllnessHumansMaleFemaleAdolescentMexicoQuality of LifeSeverity of Illness IndexBrazilChildArgentinaYoung AdultAdultPruritusMiddle Aged

Stichwörter der Autor:innen

Atopic dermatitisCost of illnessLatin AmericaTherapeutics

Autor:innen und Institutionen

  • GA(2)LEN Atopic Dermatitis Center of Reference and Excellence, Medical Specialty Unit, Secretaria de la Defensa Nacional, CDMX, Mexico. Electronic address: cide@inmunodermamexico.com.
  • Department of Dermatology, Faculty of Medicine, Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil.
  • Department of Dermatology, Faculty of Medicine, Centro Universitário Saúde ABC, Santo André, SP, Brazil.
  • Clínica de Alergía, Sorocaba, SP, Brazil.
  • Department of Dermatology, Hospital Italiano de Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina.
  • Department of Dermatology, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.

Förderung

  • Pfizer
  • AbbVie Inc

Zitieren

APA

Pérez, C. R., Aoki, V., Criado, R. F., Antila, M., Angles, M. V., Cestari, T. F., Quintero, D. G. V., Magariños, G., Castro, C., Tello-Santillán, A. L., Weber, M., Lorenzini, D., de Castro, C. C. S., Maspero, J., García-Hidalgo, L., Zhou, L., Hammad, S., de Campos, L., Rodrigues, T. C., …, & Luna, P. C. (2025). The real-world burden of atopic dermatitis: MEASURE-AD results from Brazil, Mexico, and Argentina. Anais Brasileiros de Dermatologia. https://doi.org/10.1016/j.abd.2024.05.011

Vancouver

Pérez CR, Aoki V, Criado RF, Antila M, Angles MV, Cestari TF, et al. The real-world burden of atopic dermatitis: MEASURE-AD results from Brazil, Mexico, and Argentina. Anais Brasileiros de Dermatologia. 2025. doi:10.1016/j.abd.2024.05.011

BibTeX
@article{Prez2025,
  author = {Pérez, Catalina Rincón and Aoki, Valeria and Criado, Roberta F and Antila, Martti and Angles, Maria Valeria and Cestari, Tania Ferreira and Quintero, Delfina Guadalupe Villanueva and Magariños, Gabriel and Castro, Carla and Tello-Santillán, Adriana López and Weber, Magda and Lorenzini, Daniel and de Castro, Caio Cesar Silva and Maspero, Jorge and García-Hidalgo, Linda and Zhou, Limei and Hammad, Shereen and de Campos, Lucila and Rodrigues, Tatiane Cristina and Arzelán, Carolina and Luna, Paula C},
  title = {The real-world burden of atopic dermatitis: MEASURE-AD results from Brazil, Mexico, and Argentina},
  journal = {Anais Brasileiros de Dermatologia},
  year = {2025},
  doi = {10.1016/j.abd.2024.05.011}
}
Kostenlos starten →